{"name":"AEterna Zentaris","slug":"aeterna-zentaris","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2017-01-01","label":"Macrilen first approved","drug":"Macrilen","drugSlug":"macimorelin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"AEZS-108 / zoptarelin doxorubicin","genericName":"AEZS-108 / zoptarelin doxorubicin","slug":"aezs-108-zoptarelin-doxorubicin","indication":"Ovarian cancer","status":"phase_3"},{"name":"AEZS-130 (formerly ARD-07)","genericName":"AEZS-130 (formerly ARD-07)","slug":"aezs-130-formerly-ard-07","indication":"Castration-resistant prostate cancer (CRPC)","status":"phase_3"},{"name":"Cetrorelix 78+78","genericName":"Cetrorelix 78+78","slug":"cetrorelix-78-78","indication":"Hormone receptor-positive breast cancer (in combination with endocrine therapy)","status":"phase_3"},{"name":"Cetrorelix Pamoate","genericName":"Cetrorelix Pamoate","slug":"cetrorelix-pamoate","indication":"Prostate cancer (hormone-dependent)","status":"phase_3"},{"name":"shark cartilage extract AE-941","genericName":"shark cartilage extract AE-941","slug":"shark-cartilage-extract-ae-941","indication":"Metastatic colorectal cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"L-ARG+GHRH","genericName":"L-ARG+GHRH","slug":"l-arg-ghrh","indication":"Adult growth hormone deficiency","status":"phase_3"},{"name":"Macrilen","genericName":"MACIMORELIN","slug":"macimorelin","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"AEZS-108 / zoptarelin doxorubicin","genericName":"AEZS-108 / zoptarelin doxorubicin","slug":"aezs-108-zoptarelin-doxorubicin","phase":"phase_3","mechanism":"AEZS-108 is a conjugate of a GnRH agonist (zoptarelin) linked to the chemotherapy drug doxorubicin, designed to deliver cytotoxic payload selectively to GnRH receptor-expressing cancer cells.","indications":["Ovarian cancer","Endometrial cancer"],"catalyst":""},{"name":"AEZS-130 (formerly ARD-07)","genericName":"AEZS-130 (formerly ARD-07)","slug":"aezs-130-formerly-ard-07","phase":"phase_3","mechanism":"AEZS-130 is a selective androgen receptor (AR) antagonist that blocks androgen signaling in hormone-sensitive cancers.","indications":["Castration-resistant prostate cancer (CRPC)","Hormone-sensitive prostate cancer"],"catalyst":""},{"name":"Cetrorelix 78+78","genericName":"Cetrorelix 78+78","slug":"cetrorelix-78-78","phase":"phase_3","mechanism":"Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist that suppresses luteinizing hormone and follicle-stimulating hormone to inhibit ovarian steroid production.","indications":["Hormone receptor-positive breast cancer (in combination with endocrine therapy)","Ovarian cancer (hormone-sensitive)"],"catalyst":""},{"name":"Cetrorelix Pamoate","genericName":"Cetrorelix Pamoate","slug":"cetrorelix-pamoate","phase":"phase_3","mechanism":"Cetrorelix pamoate is a gonadotropin-releasing hormone (GnRH) antagonist that blocks GnRH receptors to suppress luteinizing hormone and follicle-stimulating hormone secretion.","indications":["Prostate cancer (hormone-dependent)","Ovarian suppression in assisted reproductive technology"],"catalyst":""},{"name":"L-ARG+GHRH","genericName":"L-ARG+GHRH","slug":"l-arg-ghrh","phase":"phase_3","mechanism":"L-arginine combined with growth hormone-releasing hormone (GHRH) stimulates endogenous growth hormone secretion to promote anabolic effects and tissue repair.","indications":["Adult growth hormone deficiency","Age-related growth hormone decline / somatopause"],"catalyst":""},{"name":"Macrilen","genericName":"MACIMORELIN","slug":"macimorelin","phase":"marketed","mechanism":"Macrilen works by binding to the growth hormone secretagogue receptor type 1, triggering a response that stimulates the release of growth hormone.","indications":[],"catalyst":""},{"name":"shark cartilage extract AE-941","genericName":"shark cartilage extract AE-941","slug":"shark-cartilage-extract-ae-941","phase":"phase_3","mechanism":"AE-941, a shark cartilage extract, is thought to inhibit angiogenesis.","indications":["Metastatic colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPT1JEQlVXWGFRalVPYnBHdG45VU9WT05YMS1WbW41MkNlbzVZU0FiQzA1RlJpMlFxeVdzRS1YMlBMc3NfeTRaUXVQVHNtcTFfZXBQX2lySEJQUUw4UTMwUXM0Yk9hZFVvYktHTXBsZHNtZ2hUdFlFVzJsblNZZURHOE9NU3pnaG15Z19aS09WZURUWUVJcXFMQWV0eWNrMDRlOUI3X1V2anM3bnhKTWIweWIteVJvazQ2UUxCd21WZlBlM255V3Bfc1FHVUFIQ1lZeUtNZDg1bGNJdXU5cC1fbjBFbGQzOXg2Z2c?oc=5","date":"2025-01-30","type":"pipeline","source":"BioSpace","summary":"Growth Hormone Deficiency Market Size to Reach USD 4.5 Billion by 2035, Impelled by Advancements in Early Detection - BioSpace","headline":"Growth Hormone Deficiency Market Size to Reach USD 4.5 Billion by 2035, Impelled by Advancements in Early Detection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1fZmpQeTJxTm1lY3ZtRVFVSml2Y0VmX0VMeUlKOHVsdjRsNzNrUjRoVGRrek5mbjFxLWNrdElOcXYzODRsQl9JT0FDYjM1TTNyczRCUV8xMTQ0ZUFZY3FR?oc=5","date":"2024-08-08","type":"pipeline","source":"ChartMill","summary":"AEZS Stock Price, Quote & Chart | AETERNA ZENTARIS INC (NASDAQ:AEZS) - ChartMill","headline":"AEZS Stock Price, Quote & Chart | AETERNA ZENTARIS INC (NASDAQ:AEZS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNYjFLUllYd3M3RzMzdlVrNzJDQ05rbGNhVjFVRjlyYkdqMk9UMTNIMWpFR3dBZllhNlBXSDhWS2dTbTFwS3o2UWNxblJ5RFRyMjhYVjYzejhWbUItclRQMU94bWFlVmphX1M5SDVXZkRTb0RBM3BQTXJ2emhucGczLXdocV9QMlFuRzJQUUJjbldkMHFKbU5FWWx2UXI1emVJWnhTLURHc3puM0xfVUZpWFF6X3dYb1NjTTRiTA?oc=5","date":"2024-08-07","type":"pipeline","source":"Fierce Pharma","summary":"Aeterna Zentaris not so eternal after all as biopharma rebrands to become ‘COSCIENS Biopharma’ - Fierce Pharma","headline":"Aeterna Zentaris not so eternal after all as biopharma rebrands to become ‘COSCIENS Biopharma’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNWXYxRUF0VjVtZlBWX2hDY2taenlBVnhvS1dFR3JzbVA3RVN4djJqVmNralRvYThVVjJDR0ZjazFwX2l1V3FZa2ZRVDBFdXhNRjJEQklFT0RUZDlZQklkMG1FNkZVNmRCQW4zanRrZmU0dUEtU0p3QzQ0c3E3MUZHT3E3X3Q1dVFYREktUmU1QVVRMkNQZDB1NjhzV0VXdw?oc=5","date":"2024-08-07","type":"pipeline","source":"Contract Pharma","summary":"Aeterna Zentaris Changes Name to COSCIENS Biopharma - Contract Pharma","headline":"Aeterna Zentaris Changes Name to COSCIENS Biopharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOVlpNS2pBRThLV1k4SW1PM3F1dUVvR0hIQThCa1lDVmQ5NU84RTRmZ1pDdjdKZ2p2eUtSTk5GZGpldmZ4RGhDS2paTnRhak1tMnVxYm42eHAwNGUwMUxpLTRlUEo4UkVtYjBnTDJqdnNIQ1RJZFJCSGFYUXE5amltRVNOZER1TkRv?oc=5","date":"2024-08-06","type":"pipeline","source":"Yahoo Finance","summary":"Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. - Yahoo Finance","headline":"Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOczdxRTZNUllVLXdLYWlHYzJaTlBXWGx5VG14NXNfMk8zZFRRLVpRM0d6MVNuYTctZ3lsRVAxSkwyUExkWEJPNmNHcXVhUkIxWHRuWGl5OVFZZ3puWlJzSUNjLUFWcXZreXc0RnhVaHRHaEtMbFJtREVGamFxc3lCbHZTTS1IVWhvUHljdzZiQkh6UWItdkktbm5uUURnYUFGOUdmQVU1THBhMENWS01JUTExWTh6b2twa01OTkxCbXM3ZkpCSUE?oc=5","date":"2024-06-03","type":"deal","source":"GlobeNewswire","summary":"Aeterna Zentaris and Ceapro Complete Merger Transaction - GlobeNewswire","headline":"Aeterna Zentaris and Ceapro Complete Merger Transaction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQMVR6Rk1UUDc2eE9pY1k1aThLRC1TM08zNWg2RVFwQTRfdHNEQWxJR05FRThRN2ZnOVM0c2JHSHdKR0EzanpRdHB5b3ZxVVpQdnNkQ3JYVVA4ZG85SXlySkFJS1hiQjB3UmVFendZaVJwWkcwdGdHNGhYb3g3TVA2ZnBuZkZYQ2NZZHJFMFM0bXZ2NDRzR1JsUXRXbmtXT0pXbjZCaUhmbmM0NER6dU50N18yWWUtSWhsVXNMQWhSQVBfY05OdWtBZXRaeWJaZzRSZkw0TXRnZ25IY29sekdJZEhVSVNfc3gwanFKanNGY3dEVjVVamhqd2RMSnhmdWxyRHBFc2dR?oc=5","date":"2023-12-14","type":"deal","source":"GlobeNewswire","summary":"Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company - GlobeNewswire","headline":"Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPNXRqVi1rSG1hOHJ4YnF5a0FWc2lLbWp0UGVnYlNmVUpuWGVTNTh0WVEzUFAwRXJTMnI3YWIxcmpTbk1tMzNhNGZjbWVBLWZMZDZ0RmlucGhNRmt2YUlFYTJxenFNYXc1bXFhZUxaUUlJZ0V0a2ZTT2ZKLS1MbzZBdDlxc3diOENnUkQ0akwyZw?oc=5","date":"2023-03-17","type":"deal","source":"Pharmaceutical Technology","summary":"Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin - Pharmaceutical Technology","headline":"Pharmanovia signs licence deal for Aeterna Zentaris’ Ghryvelin","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-03-16","type":"regulatory","source":"Business Wire","summary":"Pharmanovia Enters Into an Exclusive Licensing Agreement With Aeterna Zentaris for the First and Only Orally Administered Approved Medicine for the Diagnosis of Growth Hormone Deficiency in Adults - B","headline":"Pharmanovia Enters Into an Exclusive Licensing Agreement With Aeterna Zentaris for the First and Only Orally Administere","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBKRHgxZ01YSDdGSEJTVEFvSlp6MC1obnlXQkFQVUN4WFpYWVh0Zk9hTzJQalliQmVTZ0c0aWh3NjZ4dlJQZmU5SkV0OHNIaXUzbDNnVk1aMkotWlBKUUJtWWxvd2hmSEVHRGsyWUhB0gFyQVVfeXFMTy10am93c0oxREp5YWlBenI1SlVJRmdKdVFkUFhMOUs4SG5TQ2d4VkxWQ3JET0JRUlZjYmctallwM3ZCYndsenlUQjFzUnlJZnhfNU9LQ0ZuYU1fdEJDdm5RcU1jTGFPaWJiRXE4YXJhR1NB?oc=5","date":"2022-07-07","type":"pipeline","source":"koreabiomed.com","summary":"Pharmbio Korea to supply Canada-made AGHD drug - koreabiomed.com","headline":"Pharmbio Korea to supply Canada-made AGHD drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNa0hWb2tKbkF2aWcwTlJwa1RVSVdnelNtNENQMTNWXy1STjBRZHRmdmdkVDJDeUFJNndUYUJhWmVMMXF2b3JhalJQN1dOSl84N2RFRDlSUV9sX0NHQ0UzSTU2NlR1cnZpQ2hveGdkMjlUU3dYazdyeTJ2bHExc29vOGZneV9WOGJua080QmNn?oc=5","date":"2017-07-21","type":"pipeline","source":"Fierce Biotech","summary":"Aeterna CEO Dodd out as company reviews options - Fierce Biotech","headline":"Aeterna CEO Dodd out as company reviews options","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPc0Z1NFU1QmE1RHdyNG56ZkdNT2YxV1RJekZ2MWViSGhVR2RnakpBNzZjTGx6WWNzQnEwUGY3MTVqOURLcWtYVEU0ZXNVeUVpN01oRDZfbk5TS0xqMU1zaGFXVW5BRlIwbDdZclVoSGZvTnM4UGxsNFYyVmZRRVk0dUFWSktjMjA?oc=5","date":"2017-05-02","type":"pipeline","source":"BioPharma Dive","summary":"Late-stage failure puts an end to Aeterna Zentaris’ lead therapy - BioPharma Dive","headline":"Late-stage failure puts an end to Aeterna Zentaris’ lead therapy","sentiment":"neutral"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":6,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}